PABFX
Price
$17.55
Change
-$0.99 (-5.34%)
Updated
Dec 20 closing price
RLBCX
Price
$34.14
Change
+$0.26 (+0.77%)
Updated
Dec 20 closing price
Ad is loading...

PABFX vs RLBCX

Header iconPABFX vs RLBCX Comparison
Open Charts PABFX vs RLBCXBanner chart's image
PGIM Balanced Z
Price$17.55
Change-$0.99 (-5.34%)
VolumeN/A
CapitalizationN/A
American Funds American Balanced R3
Price$34.14
Change+$0.26 (+0.77%)
VolumeN/A
CapitalizationN/A
PABFX vs RLBCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
PABFX vs. RLBCX commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PABFX is a StrongBuy and RLBCX is a Buy.

FUNDAMENTALS
Fundamentals
RLBCX has more cash in the bank: 236B vs. PABFX (952M). PABFX pays higher dividends than RLBCX: PABFX (2.31) vs RLBCX (1.98). PABFX was incepted earlier than RLBCX: PABFX (32 years) vs RLBCX (23 years). RLBCX is a more actively managed with annual turnover of: 171.00 vs. PABFX (141.00). PABFX has a lower initial minimum investment than RLBCX: PABFX (0) vs RLBCX (250). RLBCX annual gain was more profitable for investors over the last year : 9.82 vs. PABFX (8.58). RLBCX return over 5 years is better than : 28.29 vs. PABFX (18.00).
PABFXRLBCXPABFX / RLBCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence32 years23 years-
Gain YTD7.9919.23387%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets952M236B0%
Annual Yield % from dividends2.311.98117%
Returns for 1 year8.589.8287%
Returns for 3 years6.308.6972%
Returns for 5 years18.0028.2964%
Returns for 10 years33.0648.7468%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RDVT37.810.57
+1.53%
Red Violet
VRSK276.861.28
+0.46%
Verisk Analytics
CAR80.980.04
+0.05%
Avis Budget Group
ADEA13.66-0.07
-0.51%
Adeia
TPST0.71-0.01
-1.17%
Tempest Therapeutics